{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:26:06Z","timestamp":1790270766801,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.vaccine.2020.12.079","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T12:12:28Z","timestamp":1610626348000},"page":"889-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Jossy","family":"van den Boogaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brechje","family":"de Gier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"de Oliveira Bressane Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.M.","family":"Hahn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene K.","family":"Veldhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.12.079_b0005","doi-asserted-by":"crossref","unstructured":"Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301-16.","DOI":"10.1016\/j.vaccine.2011.08.061"},{"issue":"42","key":"10.1016\/j.vaccine.2020.12.079_b0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.15585\/mmwr.mm6842a1","article-title":"Global Routine Vaccination Coverage, 2018","volume":"68","author":"Peck","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.vaccine.2020.12.079_b0015","unstructured":"Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2020;95(27):301\u201324."},{"issue":"45","key":"10.1016\/j.vaccine.2020.12.079_b0020","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.15585\/mmwr.mm6645a4","article-title":"Progress in Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000\u20132016","volume":"66","author":"Grant","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.12.079_b0025","unstructured":"Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec. 2017;92(17):205-27."},{"issue":"11","key":"10.1016\/j.vaccine.2020.12.079_b0030","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1473-3099(19)30395-0","article-title":"Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis","volume":"19","author":"Nic Lochlainn","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.12.079_b0035","doi-asserted-by":"crossref","unstructured":"Reef SE, Plotkin SA. Rubella Vaccines. 7th edition ed. Stanley A Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Philadephia: Elsevier; 2018.","DOI":"10.1016\/B978-0-323-35761-6.00052-3"},{"issue":"1","key":"10.1016\/j.vaccine.2020.12.079_b0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2020.12.079_b0045","unstructured":"World Health Organization. Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome 2018 [Third edition, June 2018:[Available from: https:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/laboratory\/manual\/en\/."},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2020.12.079_b0055","doi-asserted-by":"crossref","unstructured":"The MMR-161 study group. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12\u201315months: A phase III, randomized, non-inferiority trial. Vaccine. 2018;36(38):5781-8.","DOI":"10.1016\/j.vaccine.2018.07.076"},{"key":"10.1016\/j.vaccine.2020.12.079_b0060","unstructured":"The MMR-162 study group. Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Human Vaccines and Immunotherapeutics. 2018."},{"issue":"9","key":"10.1016\/j.vaccine.2020.12.079_b0065","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.vaccine.2018.01.006","article-title":"Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: a randomized, parallel group, non-inferiority trial","volume":"36","author":"Bavdekar","year":"2018","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4161\/hv.20357","volume":"8","author":"Bryant","year":"2012","journal-title":"Human Vacc Immunotherapeutics."},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/INF.0b013e3181c15977","article-title":"Reactogenicity and immunogenicity of combined haemophilus influenzae type B-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccinehib-menc-TT booster with routine MMR vaccine","volume":"29","author":"Carmona","year":"2010","journal-title":"Pediatric Infect Disease J"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0080","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine when given with measles\u2013rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia","volume":"4","author":"Clarke","year":"2016","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.vaccine.2020.12.079_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cct.2014.11.014","article-title":"Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: A randomized non-inferiority study","volume":"41","author":"de Menezes","year":"2015","journal-title":"Contemporary Clinical Trials."},{"issue":"20","key":"10.1016\/j.vaccine.2020.12.079_b0090","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.vaccine.2015.02.070","article-title":"Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad\u00ae) administered concomitantly with a booster dose of a hexavalent vaccine in 12\u201323-month-old infants","volume":"33","author":"Deichmann","year":"2015","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2020.12.079_b0095","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2016.07.009","article-title":"The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: a phase IIIb, randomized, multi-center study in Italy","volume":"34","author":"Durando","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0100","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4161\/hv.24035","article-title":"Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial","volume":"9","author":"Huang","year":"2013","journal-title":"Human Vaccines and Immunotherapeutics."},{"issue":"41","key":"10.1016\/j.vaccine.2020.12.079_b0105","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.vaccine.2014.02.085","article-title":"Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2020.12.079_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007202","article-title":"Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubellavaricella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial","volume":"5","author":"Lalwani","year":"2015","journal-title":"BMJ Open."},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1442-200X.2010.03244.x","article-title":"Reappraisal of MMR vaccines currently used in Korea","volume":"53","author":"Lee","year":"2011","journal-title":"Pediatr Int"},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0120","doi-asserted-by":"crossref","first-page":"e1387","DOI":"10.1542\/peds.2010-2132","article-title":"Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children","volume":"128","author":"Leonardi","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0125","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.vaccine.2009.11.054","article-title":"Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children","volume":"28","author":"Lum","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0130","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1080\/21645515.2016.1165374","article-title":"A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process","volume":"12","author":"Marshall","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics."},{"key":"10.1016\/j.vaccine.2020.12.079_b0135","doi-asserted-by":"crossref","unstructured":"Matos dos Santos E, Noronha TG, Alves IS, Cruz RLS, Ferroco CLV, Brum RC, et al. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study. Memorias do Instituto Oswaldo Cruz. 2019;114:e180517.","DOI":"10.1590\/0074-02760180517"},{"key":"10.1016\/j.vaccine.2020.12.079_b0140","doi-asserted-by":"crossref","unstructured":"Matos dos Santos E, Silva e S\u00e1 GR, Siqueira MM, Martins RM, Camacho LA, von Doellinger VR, et al. Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program. Mem\u00f3rias do Instituto Oswaldo Cruz. 2014;109(3):335-9.","DOI":"10.1590\/0074-0276130351"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0145","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jpids\/piu081","article-title":"Safety and immunogenicity of human serum albumin-free MMR vaccine in US children aged 12\u201315 months","volume":"4","author":"Mufson","year":"2015","journal-title":"J Pediatric Infect Diseases Soc"},{"issue":"37","key":"10.1016\/j.vaccine.2020.12.079_b0150","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","article-title":"Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella","volume":"29","author":"Nascimento Silva","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.12.079_b0155","article-title":"A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX\u00ae","author":"Reisinger","year":"2018","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2020.12.079_b0160","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1016\/j.vaccine.2011.02.067","article-title":"Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses","volume":"29","author":"R\u00fcmke","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.12.079_b0165","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/21645515.2017.1302629","article-title":"Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27\/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial","volume":"13","author":"Sood","year":"2017","journal-title":"Human Vacc Immunotherapeut"},{"issue":"25","key":"10.1016\/j.vaccine.2020.12.079_b0170","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0175","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/INF.0b013e3181dffabf","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatric Infectious Disease J"},{"issue":"18","key":"10.1016\/j.vaccine.2020.12.079_b0180","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.vaccine.2015.03.017","article-title":"M-M-R\u00aeII manufactured using recombinant human albumin (rHA) and M-M-R\u00aeII manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children","volume":"33","author":"Wiedmann","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.12.079_b0185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3329\/bmrcb.v42i2.32052","article-title":"Rubella antibody prevalence and immunogenicity of single dose rubella vaccine among 16\u201325 years girls from Bangladesh","volume":"42","author":"Nessa","year":"2016","journal-title":"Bangladesh Med Res Counc Bull"},{"issue":"1","key":"10.1016\/j.vaccine.2020.12.079_b0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/0970-0218.62575","article-title":"Sero-Surveillance to assess immunity to rubella and assessment of immunogenicity and safety of a single dose of rubella vaccine in school girls","volume":"35","author":"Sharma","year":"2010","journal-title":"Indian J Comm Med"},{"issue":"12","key":"10.1016\/j.vaccine.2020.12.079_b0195","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3855\/jidc.1847","article-title":"Seroprevalence of rubella and immunogenicity following rubella vaccination in adolescent girls in India","volume":"5","author":"Sharma","year":"2011","journal-title":"J Infect Dev Countries"},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/hv.18650","volume":"8","author":"Ferrera","year":"2012","journal-title":"Human Vacc Immunotherap"},{"issue":"9","key":"10.1016\/j.vaccine.2020.12.079_b0205","first-page":"302","article-title":"Immune response to second dose of MMR vaccine in Indian children","volume":"134","author":"Gomber","year":"2011","journal-title":"Indian J Med Res"},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00431-011-1569-4","article-title":"Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children","volume":"171","author":"Knuf","year":"2012","journal-title":"Eur J Pediatr"},{"issue":"17","key":"10.1016\/j.vaccine.2020.12.079_b0215","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.vaccine.2018.03.021","volume":"36","author":"Marlow","year":"2018","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2020.12.079_b0220","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.vaccine.2012.02.062","article-title":"Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad\u00ae) in infants from 9 months of age","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0225","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(18)30650-9","article-title":"Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14\u201314\u20132 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial","volume":"19","author":"Li","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2020.12.079_b0230","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.vaccine.2014.04.044","volume":"32","author":"He","year":"2014","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7883\/yoken.JJID.2015.162","article-title":"Persistence of immunity acquired after a single dose of rubella vaccine in Japan","volume":"69","author":"Okafuji","year":"2016","journal-title":"Japanese J Infect Diseases"},{"issue":"32","key":"10.1016\/j.vaccine.2020.12.079_b0240","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1016\/j.vaccine.2011.05.046","article-title":"Persistence of antibodies in 4\u20138 year old austrian children after vaccination with hexavalent DTaP-HBV-IPV\/Hib and MMR vaccines","volume":"29","author":"Paulke-Korinek","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.12.079_b0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1620\/tjem.246.73","article-title":"Vaccination status and antibody titers against rubella and measles among japanese female college students majoring in childcare between 2015 and 2018","volume":"246","author":"Shoho","year":"2018","journal-title":"Tohoku J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2020.12.079_b0250","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/infdis\/jiw058","article-title":"Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months","volume":"213","author":"Kontio","year":"2016","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0255","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/tropej\/fmp104","article-title":"Effect of season of inoculation on immune response to rubella vaccine in children","volume":"57","author":"Linder","year":"2011","journal-title":"J Trop Pediatr"},{"issue":"23","key":"10.1016\/j.vaccine.2020.12.079_b0260","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/j.vaccine.2017.04.027","article-title":"Antibody persistence in children aged 6\u20137 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection","volume":"35","author":"D\u00edaz Ortega","year":"2017","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2020.12.079_b0265","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1016\/j.vaccine.2010.08.055","article-title":"Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route","volume":"28","author":"D\u00edaz-Ortega","year":"2010","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2020.12.079_b0270","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1016\/j.vaccine.2018.08.010","article-title":"Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults","volume":"36","author":"McLean","year":"2018","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2020.12.079_b0275","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1017\/S0950268816001655","article-title":"Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal","volume":"144","author":"Gon\u00e7alves","year":"2016","journal-title":"Epidemiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2020.12.079_b0280","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/infdis\/jis568","article-title":"Waning antibody levels and avidity: Implications for MMR vaccine-induced protection","volume":"206","author":"Kontio","year":"2012","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0285","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.vaccine.2017.12.075","article-title":"Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine","volume":"36","author":"Seagle","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.12.079_b0290","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.vaccine.2013.10.070","article-title":"A rubella outbreak investigation and BRD-II strain rubella vaccine effectiveness study, Harbin city, Heilongjiang province, China, 2010\u20132011","volume":"32","author":"Xu","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.12.079_b0295","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archpedi.1969.02100040303027","article-title":"Prevention of rubella during an epidemic on Taiwan. HPV-77 and RA 27\u20133 rubella vaccines administered subcutaneously and intranasally HPV-77 vaccine mixed with mumps and-or measles vaccines","volume":"118","author":"Beasley","year":"1969","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2020.12.079_b0300","unstructured":"de Valk H., I. R. Epid\u00e9mie de rub\u00e9ole: Evaluation de l\u2019efficacit\u00e9 vaccinale sur le terrain, Ard\u00e8che, janvier mars 1997. R\u00e9seau National de Sant\u00e9 Publique. 1998(Jan):1-52."},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0305","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/jama.1970.03170320015002","article-title":"Rubella vaccination during an epidemic","volume":"213","author":"Furukawa","year":"1970","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2020.12.079_b0310","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/INF.0b013e3181a3e2d5","article-title":"Rubella outbreak in the Netherlands, 2004\u20132005: high burden of congenital infection and spread to Canada","volume":"28","author":"Hahne","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2020.12.079_b0315","first-page":"2624","article-title":"Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: a phase III, randomized study","volume":"14","author":"Abu-Elyazeed","year":"2018","journal-title":"Human Vacc Immunotherapeutics"},{"issue":"7","key":"10.1016\/j.vaccine.2020.12.079_b0320","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1080\/21645515.2017.1309486","article-title":"Two-year antibody persistence in children vaccinated at 12\u201315 months with a measles-mumps-rubella virus vaccine without human serum albumin","volume":"13","author":"Berry","year":"2017","journal-title":"Human Vacc Immunotherapeutics"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0325","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/INF.0b013e318259fc8a","article-title":"Immunogenicity and Safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age","volume":"31","author":"Blatter","year":"2012","journal-title":"Pediatric Infectious Disease J"},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0330","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/21645515.2018.1425659","article-title":"Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study","volume":"14","author":"Chiu","year":"2018","journal-title":"Human Vacc Immunotherapeut"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0335","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/INF.0000000000000752","article-title":"First experience of concomitant vaccination against dengue and MMR in toddlers","volume":"34","author":"Crevat","year":"2015","journal-title":"Pediatric Infect Disease J."},{"issue":"29","key":"10.1016\/j.vaccine.2020.12.079_b0340","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.vaccine.2014.04.031","article-title":"Booster immune response in children 6\u20137 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection","volume":"32","author":"D\u00edaz-Ortega","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0345","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1542\/peds.2011-3198","article-title":"Measles-containing vaccines and febrile seizures in children age 4 to 6 years","volume":"129","author":"Klein","year":"2012","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0350","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00431-010-1142-6","article-title":"Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11\u201321 months","volume":"169","author":"Knuf","year":"2010","journal-title":"Eur J Pediatr"},{"issue":"11","key":"10.1016\/j.vaccine.2020.12.079_b0355","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/INF.0b013e318268dfe4","article-title":"Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies","volume":"31","author":"Pina","year":"2012","journal-title":"Pediatric Infect Disease J"},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0360","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1473-3099(18)30716-3","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial","volume":"19","author":"Povey","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2020.12.079_b0365","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1097\/INF.0b013e31822256a5","article-title":"Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age","volume":"30","author":"Rinderknecht","year":"2011","journal-title":"Pediatric Infect Disease J"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0370","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4161\/hv.24873","article-title":"Concomitant administration of hepatitis A vaccine with measles\/mumps\/ rubella\/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children","volume":"9","author":"Yetman","year":"2013","journal-title":"Human Vacc Immunotherapeut"},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0375","article-title":"Immunogenicity and safety of an inactivated hepatitis A vaccine given with measles-mumps-rubella vaccine to 12\u201313 month old Turkish children","volume":"3","author":"Yurdak\u00f6k","year":"2012","journal-title":"J Vacc Vaccinat"},{"issue":"49","key":"10.1016\/j.vaccine.2020.12.079_b0380","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1016\/j.vaccine.2012.09.053","article-title":"Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak","volume":"30","author":"Abedi","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0385","first-page":"230","article-title":"Study of adverse events following immunisation with universal and newer vaccines in the Serampore IMA Child Clinic over a period of 7 years","volume":"111","author":"Das","year":"2013","journal-title":"J Indian Med Assoc"},{"issue":"2","key":"10.1016\/j.vaccine.2020.12.079_b0390","first-page":"152","article-title":"MMR vaccine in the postpartum does not expose seronegative women to untoward effects","volume":"53","author":"Finale","year":"2017","journal-title":"Annali dell'Istituto superiore di sanita."},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0395","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00431-010-1294-4","article-title":"Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children","volume":"170","author":"Kemmeren","year":"2011","journal-title":"Eur J Pediatr"},{"issue":"11","key":"10.1016\/j.vaccine.2020.12.079_b0400","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/INF.0b013e318267fd8b","article-title":"Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin","volume":"31","author":"R\u00fcger","year":"2012","journal-title":"Pediatric Infect Disease J"},{"issue":"9","key":"10.1016\/j.vaccine.2020.12.079_b0405","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/infdis\/jiv756","article-title":"Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6\u201314 Months during a Measles Outbreak in the Netherlands in 2013\u20132014","volume":"213","author":"Van Der Maas","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.12.079_b0410","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/21645515.2017.1384105","article-title":"Reporting of adverse events following immunizations in Ghana-Using disproportionality analysis reporting ratios","volume":"14","author":"Ankrah","year":"2018","journal-title":"Human Vacc Immunotherapeut"},{"key":"10.1016\/j.vaccine.2020.12.079_b0415","doi-asserted-by":"crossref","unstructured":"Cunha MPL, D\u00f3rea JG, Marques RC, Le\u00e3o RS. Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil. BioMed Research International. 2013;2013.","DOI":"10.1155\/2013\/853083"},{"issue":"39","key":"10.1016\/j.vaccine.2020.12.079_b0420","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.vaccine.2010.07.043","article-title":"Impact of unfounded vaccine safety concerns on the nationwide measles-rubella immunization campaign, Georgia, 2008","volume":"28","author":"Khetsuriani","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2020.12.079_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15061149","article-title":"Adverse events following immunization in Brazil: age of child and vaccine-associated risk analysis using logistic regression","volume":"15","author":"Lopes","year":"2018","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2020.12.079_b0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172108","article-title":"Safety of measles-containing vaccines in postmarketing surveillance in Anhui, China","volume":"12","author":"Meng","year":"2017","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.vaccine.2020.12.079_b0435","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00103-013-1792-4","article-title":"Safety and tolerability of monovalent measles and combined measles, mumps, rubella, and varicella vaccines [In German]","volume":"56","author":"Mentzer","year":"2013","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz."},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0440","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.anpedi.2012.07.013","article-title":"Suspected adverse events to measles, mumps and rubella vaccine reported to the Community of Valencia Pharmacovigilance Centre [in Spanish]","volume":"78","author":"P\u00e9rez-Vilar","year":"2013","journal-title":"Anales de Pediatria."},{"issue":"10","key":"10.1016\/j.vaccine.2020.12.079_b0445","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1093\/cid\/civ061","article-title":"Adverse events following measles, mumps, and rubella vaccine in adults reported to the vaccine adverse event reporting system (VAERS), 2003\u20132013","volume":"60","author":"Sukumaran","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2020.12.079_b0450","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1097\/INF.0000000000001201","article-title":"Adverse events after MMR or MMRV vaccine in infants under nine months old","volume":"35","author":"Woo","year":"2016","journal-title":"Pediatric Infectious Disease J"},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0455","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5144\/0256-4947.2015.254","article-title":"Acute hemorrhagic edema of infancy after MMR vaccine","volume":"35","author":"Binamer","year":"2015","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.vaccine.2020.12.079_b0460","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-12-105","article-title":"Recurrent 6th nerve palsy in a child following different live attenuated vaccines: case report","volume":"12","author":"Cheng","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0465","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1542\/peds.2012-2930","article-title":"Anterior uveitis and cataract after rubella vaccination: A case report of a 12-month-old girl","volume":"132","author":"Ferrini","year":"2013","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0470","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1515\/rrlm-2016-0028","article-title":"Severe pneumococcal pneumonia following Measles- Mumps- Rubella vaccination","volume":"24","author":"G\u00e1l","year":"2016","journal-title":"Revista Romana de Medicina de Laborator."},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0475","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1346-8138.2011.01380.x","article-title":"Pityriasis lichenoides chronic after measles-mumps-rubella vaccination","volume":"39","author":"Gil-Bistes","year":"2012","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0480","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcv.2013.10.016","article-title":"Fulminant encephalitis associated with a vaccine strain of rubella virus","volume":"58","author":"Gualberto","year":"2013","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.12.079_b0485","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/j.1440-0960.2011.00781.x","article-title":"Pityriasis lichenoides et varioliformis acuta: A rare association with the measles, mumps and rubella vaccine","volume":"53","author":"Gunatheesan","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0490","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaophthalmol.2017.0380","article-title":"Acute bilateral photoreceptor degeneration in an infant after vaccination against measles and rubella","volume":"135","author":"Kuniyoshi","year":"2017","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10.1016\/j.vaccine.2020.12.079_b0495","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1824-7288-36-59","article-title":"Partial third nerve palsy after Measles Mumps Rubella vaccination","volume":"36","author":"Manzotti","year":"2010","journal-title":"Italian J Pediatr"},{"issue":"11","key":"10.1016\/j.vaccine.2020.12.079_b0500","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.annder.2011.01.049","article-title":"Pityriasis rubra pilaris after vaccination [in French]","volume":"138","author":"Naciri Bennani","year":"2011","journal-title":"Ann Dermatol Venereol"},{"issue":"31","key":"10.1016\/j.vaccine.2020.12.079_b0505","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1016\/j.vaccine.2011.04.036","article-title":"Detection of platelet-binding anti-measles and anti-rubella virus IgG antibodies in infants with vaccine-induced thrombocytopenic purpura","volume":"29","author":"Okazaki","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0510","first-page":"1053","article-title":"Measles-mumps-rubella vaccination induced thrombocytopenia: a case report and review of the literature","volume":"45","author":"Owatanapanich","year":"2014","journal-title":"The Southeast Asian J Trop Med Public Health"},{"issue":"12","key":"10.1016\/j.vaccine.2020.12.079_b0515","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1007\/s00296-011-2130-5","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment","volume":"32","author":"Sanz","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.vaccine.2020.12.079_b0520","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/00365548.2010.513067","article-title":"Suspected measles-mumps-rubella vaccine-related encephalitis: two cases","volume":"43","author":"Shuper","year":"2010","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.12.079_b0525","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5152\/tjg.2016.0559","article-title":"Pancreatic pseudocyst after measles, mumps, and rubella vaccination","volume":"28","author":"Verma","year":"2017","journal-title":"Turkish J Gastroenterol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.12.079_b0530","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/pde.13532","article-title":"Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: a case report and review of the literature","volume":"35","author":"Yu","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"SUPPL. 2","key":"10.1016\/j.vaccine.2020.12.079_b0535","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1093\/infdis\/jir489","article-title":"Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001\u20132008","volume":"204","author":"Castillo-Sol\u00f3rzano","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2020.12.079_b0540","first-page":"230","article-title":"Rubella vaccination during the preconception period or in pregnancy and perinatal and fetal outcomes","volume":"54","author":"Ergeno\u01e7lu","year":"2012","journal-title":"Turkish J Pediatr"},{"key":"10.1016\/j.vaccine.2020.12.079_b0545","unstructured":"WHO. Measles and rubella surveillance data (2015-2019) [Available from: https:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/vpd\/surveillance_type\/active\/measles_monthlydata\/en\/."},{"key":"10.1016\/j.vaccine.2020.12.079_b0550","unstructured":"Steward MW, Chargelegue D. Overview: measurement and biological significance of antibody affinity and reactivity. Weir DM, Herzenberg LA, Blackwell CC, editors. Oxford, UK: Blackwell; 1997."},{"key":"10.1016\/j.vaccine.2020.12.079_b0555","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.vaccine.2019.11.070","article-title":"Safety profile of rubella vaccine administered to pregnant women: a systematic review of pregnancy related adverse events following immunisation, including congenital rubella syndrome and congenital rubella infection in the foetus or infant","volume":"38","author":"Mangtani","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.12.079_b0560","doi-asserted-by":"crossref","unstructured":"Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4:CD004407.","DOI":"10.1002\/14651858.CD004407.pub4"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20316911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20316911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:26Z","timestamp":1759402346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20316911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0264410X20316911"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}